Global Epilepsy Drugs Market Report 2024

The epilepsy drugs market size has grown strongly in recent years. It will grow from $9.59 billion in 2023 to $10.34 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth observed during the historic period can be attributed to several factors, including the development of antiepileptic drugs, advancements in diagnostic techniques, an increased understanding of epilepsy's neurological basis, a growing demand for epilepsy treatment, and regulatory approvals for new medications.

The epilepsy drugs market size is expected to see rapid growth in the next few years. It will grow to $14.03 billion in 2028 at a compound annual growth rate (CAGR) of 8%. The anticipated growth in the forecast period can be attributed to several factors, including the expansion of personalized medicine, adoption of novel drug delivery methods, emergence of digital health solutions, increased investment in research and development (R&D), and integration of artificial intelligence (AI) and machine learning (ML). Major trends expected in the forecast period include a shift towards combination therapies, the rise of telemedicine, a focus on drug-resistant epilepsy, integration of genetic testing, and the utilization of wearable devices.

The anticipated increase in the number of people affected by epilepsy is expected to drive the growth of the epilepsy drug market in the coming years. Epilepsy is a neurological disorder characterized by recurrent seizures of varying severity, which can significantly impact daily life. This condition is more prevalent among older age groups, and individuals who have experienced traumatic brain injuries (TBIs), strokes, brain tumors, or other neurological conditions are at higher risk of developing epilepsy. Epilepsy drugs function by stabilizing electrical activity in the brain, thereby reducing the frequency and severity of seizures and aiding in the management and control of epilepsy. For instance, as per the February 2024 report from the World Health Organization, approximately 5 million individuals worldwide receive an epilepsy diagnosis annually. High-income countries report an estimated 49 cases per 100,000 people annually, while in low- and middle-income nations, this rate can soar to 139 cases per 100,000. Thus, the increasing number of people affected by epilepsy is a driving force behind the growth of the epilepsy drug market.

Key players in the epilepsy drug market are concentrating on developing innovative treatments to enhance seizure control and improve patient quality of life. These innovative treatments may involve novel drug formulations, advanced neurostimulation techniques, precision medicine approaches tailored to individual patients, gene therapies, and emerging technologies such as closed-loop systems for seizure detection and intervention. For example, in January 2024, Akumentis Healthcare, an India-based pharmaceutical company, introduced Clasepi, a prescription cannabidiol (CBD) drug specifically formulated to treat seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older. Approved by the Drug Controller General of India (DCGI), Clasepi has demonstrated efficacy in reducing seizures, particularly in cases where conventional anti-seizure medications have been ineffective.

In April 2024, Harmony Biosciences, a US-based biopharmaceutical company, acquired Epygenix Therapeutics Inc for an undisclosed amount. This acquisition strengthens Harmony Biosciences' epilepsy treatment portfolio, expands its market reach, and enhances its research and development capabilities. Epygenix Therapeutics Inc, based in the US, is a precision medicine-based biopharmaceutical company focused on developing drugs to treat rare and intractable forms of genetic epilepsy.

Major companies operating in the epilepsy drugs market are Pfizer Inc, SK Biopharmaceuticals, Sanofi, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, H. Lundbeck, Viatris, Otsuka America Pharmaceutical Inc, Bausch Health Companies Inc, UCB S.A, Sun Pharmaceutical Industries Ltd, Eisai Co Ltd, Sumitomo Pharma Co Ltd, Jazz Pharmaceuticals plc, Dr. Reddy's Laboratories Ltd, Angelini S.p.a, Amneal Pharmaceuticals, Alkem Laboratories, Sunovion Pharmaceuticals Inc, Upsher-Smith, Zogenix, Neurelis Inc.

North America was the largest region in the epilepsy drugs market in 2023. The regions covered in the epilepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epilepsy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Epilepsy drugs, also referred to as antiepileptic drugs (AEDs) or antiseizure medications, are utilized to manage and control seizures in individuals diagnosed with epilepsy. Epilepsy, a neurological disorder characterized by recurring seizures, manifests in various types, severities, and frequencies. These medications operate by stabilizing electrical activity within the brain, thereby decreasing the likelihood of seizures.

The primary types of seizures targeted by epilepsy drugs include focal seizures, generalized seizures, and non-epileptic seizures. Focal seizures originate in a specific area of the brain, leading to localized symptoms. These drugs are categorized into first-generation, second-generation, and third-generation anti-epileptics, administered through routes such as oral, intravenous, and intra-muscular, and are distributed through drug stores, retail pharmacies, and hospital pharmacies.

The epilepsy drugs research report is one of a series of new reports that provides epilepsy drugs market statistics, including the epilepsy drugs industry's global market size, regional shares, competitors with an epilepsy drugs market share, detailed epilepsy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the epilepsy drugs industry. This epilepsy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The epilepsy drugs market consists of sales of carbamazepine, lamotrigine, phenobarbital, phenytoin, and valproic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.